Masha Stromme

Mentor at Nordic Mentor Network For Entrepreneurship - NOME
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
NO

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • Denmark
    • Business Consulting and Services
    • 1 - 100 Employee
    • Mentor
      • Jun 2018 - Present

    • Belgium
    • Government Administration
    • 200 - 300 Employee
    • Jury Member
      • Jun 2021 - Present

    • Australia
    • Biotechnology
    • 1 - 100 Employee
    • Member of the Board
      • Aug 2021 - Present

  • Hemispherians AS
    • Oslo, Norway
    • Member of the Board of Directors
      • Jan 2021 - Present

  • PAACS Invest AS
    • Oslo, Norway
    • Co-Chair PAACS Invest
      • Sep 2015 - Present

  • Exact Therapeutics AS
    • Oslo Area, Norway
    • Vice Chair of the Board of Directors
      • Jun 2018 - Present

  • PubGene Inc
    • Oslo Area, Norway
    • Member of the Board of Directors
      • Mar 2019 - Present

    • Partner
      • Sep 2012 - Present

      Advise and invest in healthcare companies. Current focus on medical technology and elderly care Advise and invest in healthcare companies. Current focus on medical technology and elderly care

    • Norway
    • Non-profit Organizations
    • 1 - 100 Employee
    • Advisor
      • May 2014 - Dec 2020

    • Member Board of Directors
      • Jun 2015 - Jun 2018

      First external investor in Phoenix Solutions AS, a Norwegian biotech company spun out from GE Healthcare in 2013, currently developing a technology platform for targeted drug delivery – Acoustic Cluster Therapy (ACT®). ACT® is a unique approach to ultrasound (US) mediated, targeted drug delivery – capable of enhancing significantly the clinical utility of a wide range of therapeutic molecules and nano-drugs for a wide range of clinical indications. ACT®`s primary mode of action is in defeating the vascular barrier and enhancing extravasation for greater distribution and uptake of a co-administered drug to the targeted tissue, with resulting increased efficacy and/or reduction in toxicity.

    • Norway
    • Biotechnology Research
    • 1 - 100 Employee
    • Member Board of Directors
      • Jun 2015 - May 2018

    • Investment Banking
    • 100 - 200 Employee
    • Advisor to the Healthcare Team
      • Jan 2015 - Apr 2018

    • Norway
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Member Board of Directors
      • Jan 2008 - Oct 2016

Education

  • University of Oxford
    D.Phil, Biochemistry, genetics and neuroscience
    1993 - 1997
  • McGill University
    Bachelor of Science (BSc), Biology, General
    1990 - 1993

Community

You need to have a working account to view this content. Click here to join now